Advanced Filters
noise

Oak Park, Illinois Clinical Trials

A listing of Oak Park, Illinois clinical trials actively recruiting patient volunteers.

Found 1,430 clinical trials

A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)

The purpose of this study is to learn more about the safety, effectiveness and tolerability of the study drug called Benfotiamine which may delay or slow the progression of the symptoms of early Alzheimer's disease.

50 - 89 years of age All Phase 2
T Tanvi Bhatt, PhD

Alternative Therapies for Improving Physical Function in Individuals With Stroke

Neurological impairment is a devastating disease for patients and their families and a leading cause of adult disability. Traditional rehabilitative therapies can help regain motor function and ameliorate disability. However, health care reimbursed rehabilitation is usually provided for up to 6 months post stroke (3 months in form of inpatient …

18 - 90 years of age All Phase N/A
T Tanvi Bhatt, PhD

Reactive Balance Training for Fall Prevention

The objective of this pilot study is to evaluate and compare the effect of three different perturbation based training devices on the reactive balance control among healthy young adults, healthy older adults, and neurologically impaired stroke individuals. Furthermore, the project aims to determine the feasibility and tolerability of 30-minutes of …

18 - 90 years of age All Phase N/A
E Endri Angjeli

Clinical Data Registry of Amblyopia Patients on Luminopia Treatment

Amblyopia is the most prevalent cause of reduced monocular visual acuity in children and young adults, with estimates of prevalence ranging from 1% to 5%. The most common associated amblyogenic risk factors are uncorrected anisometropia, strabismus, or a combination of these. In addition to reduced visual acuity, amblyopic patients may …

years of age All Phase N/A
J Jennifer Martinez

TEMPUS ARIES: A Biobank Registry Platform Study in Oncology

This study is a non-interventional, multicenter, multicohort evaluation of participants with cancer who will undergo longitudinal plasma ctDNA biomarker profiling at specific time points in addition to standard of care therapy.

18 - 99 years of age All Phase N/A
J Jaime Stokke, MD

A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

This clinical trial will test the safety and efficacy of combining trametinib and azacitidine in patients with juvenile myelomonocytic leukemia (JMML). Newly diagnosed lower-risk JMML patients will receive trametinib and azacitidine. High-risk JMML patients will receive trametinib, azacitidine, fludarabine, and cytarabine.

1 - 21 years of age All Phase 1/2
J Jennifer Baker, MA

Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease

The main goals of this clinical study are to characterize safety and PK/PD of AMT-191 i.e. if drug doses used in the study are safe and tolerable and to understand how it acts in the body of people with Fabry disease.

18 - 50 years of age Male Phase 1/2
S Suzanne Finucane

Understanding How Powered Componentry Impacts K2-Level Transfemoral Amputee Gait

The goal of this study is to understand how providing power at the knee or ankle individually, or providing power at both the knee and ankle, impacts ambulation for K2 level transfemoral amputees. Aim 1: measure functional performance of K2 level ambulators when using a commercially available passive microprocessor knee …

18 - 95 years of age All Phase N/A
A Amy Heimberger

WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

This phase II trial tests how well the combination of WP1066 and radiation therapy works in treating newly diagnosed glioblastoma. Glioblastoma is difficult to treat effectively because the cells within the tumor vary widely and are controlled by factors within and around the tumor, requiring multiple approaches to treat the …

18 years of age All Phase 2
S Site Public Contact

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML): 1) daunorubicin and cytarabine liposome alone; 2) cytarabine and daunorubicin with venetoclax; 3) azacitidine and …

18 - 59 years of age All Phase 2

Simplify language using AI